go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

sanofi-aventis

sanofi-aventis
Citywest Business Campus, Dublin 24, Ireland
Telephone: +353 1 4035600
Fax: +353 1 4035687
Medical Information e-mail: IEmedinfo@sanofi-aventis.com


Summary of Product Characteristics last updated on medicines.ie: 15/03/2010
SPC Brolene 0.1%w/v Eye Drops Solution

Table of Contents

  • 1. NAME OF THE MEDICINAL PRODUCT
  • 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
  • 3. PHARMACEUTICAL FORM
  • 4. CLINICAL PARTICULARS
  • 4.1 Therapeutic indications
  • 4.2 Posology and method of administration
  • 4.3 Contraindications
  • 4.4 Special warnings and precautions for use
  • 4.5 Interaction with other medicinal products and other forms of interaction
  • 4.6 Pregnancy and lactation
  • 4.7 Effects on ability to drive and use machines
  • 4.8 Undesirable effects
  • 4.9 Overdose
  • 5. PHARMACOLOGICAL PROPERTIES
  • 5.1 Pharmacodynamic properties
  • 5.2 Pharmacokinetic properties
  • 5.3 Preclinical safety data
  • 6. PHARMACEUTICAL PARTICULARS
  • 6.1 List of excipient(s)
  • 6.2 Incompatibilities
  • 6.3 Shelf life
  • 6.4 Special precautions for storage
  • 6.5 Nature and contents of container
  • 6.6 Special precautions for disposal and other handling
  • 7. MARKETING AUTHORISATION HOLDER
  • 8. MARKETING AUTHORISATION NUMBER(S)
  • 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
  • 10. DATE OF REVISION OF THE TEXT


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Brolene 0.1%w/v Eye Drops Solution.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Propamidine isetionate 0.1% w/v.

Excipients:contains benzalkonium chloride solution 0.01%v/v.

For a full list of excipients, see section 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Eye drops solution (eye drops).

A clear, colourless, sterile, aqueous solution.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

As an anti-infective for use in local infections of the superficial structures of the eye due to microorganisms sensitive to its action.


Go to top of the page
4.2 Posology and method of administration

For ocular use.

The usual dosage is 1-2 drops into the affected eye up to four times daily.


Go to top of the page
4.3 Contraindications

Hypersensitivity to any component of the preparation.

Use of contact lenses


Go to top of the page
4.4 Special warnings and precautions for use

If there is no significant improvement within 2 days medical advice should be sought.

There is always the possibility, although rare, of a sensitisation reaction resulting from the use of Brolene preparations. In such an event treatment should be discontinued immediately. Should erythema or other evidence of increased inflammation occur application should cease immediately and medical opinion should be sought.

If problems of visual acuity occur or its symptoms are detected, the doctor should be consulted immediately.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

Safety of use in pregnancy and lactation has not been established. Use during pregnancy and lactation only if considered essential by the physician.


Go to top of the page
4.7 Effects on ability to drive and use machines

Brolene Eye Drops may cause transient blurring of vision on instillation. Patients should be warned not to drive or operate machinery unless vision is clear.


Go to top of the page
4.8 Undesirable effects

Hypersensitivity may occur, in which case treatment should be discontinued immediately.

Eye pain or irritation, usually in the form of a stinging or burning sensation, may also occur. In such cases, use should be discontinued immediately and a physician should be consulted.


Go to top of the page
4.9 Overdose

Topical overdose is not applicable. Oral ingestion of a full 10ml bottle is unlikely to cause any toxic effects.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Propamidine is a member of the aromatic diamidine group of compounds which possess bacteriostatic properties against a wide range of organisms. These diamidines exert antibacterial action against pyrogenic cocci, antibiotic resistant staphylococci and some gram-negative bacilli. The activity of the diamidines is retained in the presence of organic matter such as tissue fluids, pus, and semen.


Go to top of the page
5.2 Pharmacokinetic properties

None stated.


Go to top of the page
5.3 Preclinical safety data

There is no other information available which could be of relevance to the prescriber in recognising the safety profile of Brolene and which is not included in the relevant sections of this SPC.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipient(s)

Ammonium chloride

Sodium chloride

Benzalkonium chloride solution

Water for injections

Sodium hydroxide (for pH adjustment)


Go to top of the page
6.2 Incompatibilities

Not applicable.


Go to top of the page
6.3 Shelf life

Unopened: 2 years.

Opened: The drops should be discarded 28 days after first opening for domiciliary use or after 7 days when used under hospital conditions.


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C.


Go to top of the page
6.5 Nature and contents of container

Low density polyethylene bottle and plug with high density polyethylene tamperproof cap containing 10ml of solution, packaged in a cardboard carton.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

sanofi-aventis Ireland Ltd .

Citywest Business Campus,

Dublin 24.


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PA 540/94/1


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

1 April 1983 / 1 April 2008


Go to top of the page
10. DATE OF REVISION OF THE TEXT

February 2010



Link to this document from your website:
http://www.medicines.ie/medicine/1843/SPC/Brolene+0.1+w+v+Eye+Drops+Solution/

Document Links

 
  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Legal Categories

 
   Product subject to medical
prescription which may not
be renewed (A)
   Product subject to medical
prescription which may
be renewed (B)
   Product subject to
restricted prescription
(C)
   Supply through
general sale
   Supply through
pharmacy only

Active Ingredients

 
   Propamidine Isethionate

  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo